We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Type 2 Diabetes Associated with Arrhythmic Daily Gut Microbe

By LabMedica International staff writers
Posted on 16 Jul 2020
Print article
Image: Arrhythmic Gut Microbiome Signatures Predict Risk of Type 2 Diabetes (Photo courtesy of Technical University of Munich).
Image: Arrhythmic Gut Microbiome Signatures Predict Risk of Type 2 Diabetes (Photo courtesy of Technical University of Munich).
Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss.

Several studies found that obesity-related changes in the gut microbiota are associated with low grade inflammation, which supports a close link between the immune and metabolic systems throughout the gut microbiota. There are several mechanisms that relate microbiota to the onset of insulin resistance and diabetes, including changes in bowel permeability, endotoxemia, interaction with bile acids, changes in the proportion of brown adipose tissue.

A large team of scientists collaborating with the Technical University of Munich (Freising, Germany) used high-throughput 16S ribosomal RNA gene sequencing to profile gut microbial community composition in fecal samples from 1,976 individuals from Germany enrolled in the prospective KORA population study, detecting distinct levels of specific pathogens across the day in individuals with available time of defecation data.

By analyzing the diurnal gut microbiome dynamics, the team noted that individuals that had T2D or were obese appeared to lose gut oscillations that involved changes in microbiome levels of dozens of gut bacteria. The authors noted that while both obesity and T2D coincided with altered gut microbiome oscillations during the span of a day, there were differences in the operational taxa units involved, hinting that weight contributes to T2D risk stratification independent of disrupted circadian rhythms in the microbiome. Shotgun metagenomic analysis functionally linked 26 metabolic pathways to the diurnal oscillation of gut bacteria.

The team went on to verify the 24-hour gut microbe rhythms in nearly 1,400 more German participants sampled at multiple time points. They also used an unsupervised machine learning method to focus in on a set of 13 oscillating gut bacteria with circadian patterns that are upset in individuals with T2D. The bacterial signature showed promise for finding and predicting T2D cases in a subset of 699 participants from the KORA cohort, while additional metagenomic sequence data for a subset of 50 study participants with or without T2D or pre-diabetes, each tested twice five years apart, provided a window into some of the gut microbe genes and pathways that are altered when metabolic disease-related microbe oscillations are upended.

Dirk Haller, PhD, holds the Chair of Nutrition and Immunology and is the senior author of the study, said, “We demonstrated that loss of circadian rhythmicity affects microbiome features related to the onset and progression of T2D and identified bacterial signatures for metabolic risk profiling in human populations.”

The authors concluded that it may be important to take circadian gut microbe oscillations into account to better understand the underlying mechanisms of disease-associated microbiome alterations and to validate risk profiles in prospective cohorts. The study was published on July 2, 2020 in the journal Cell Host & Microbe.

Related Links:
Technical University of Munich

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.